Sarepta Pursues DMD Gene Therapy Accelerated Approval To Be First To Market

New Data Analyses Swayed US FDA To Allow Early Filing

Sarepta has experience pursuing accelerated approvals in the US for Duchenne muscular dystrophy therapies, but with a costly gene therapy will payers require data from a controlled Phase III study?

Sport car speedometer for hud background. Gauge control with numbers for speed measurement. Analog tachometer, high performance theme
Sarepta hopes to fast-track SRP-9001 to DMD patients • Source: Shutterstock

It may not seem like Sarepta Therapeutics, Inc. is taking a big risk by pursuing accelerated approval of Duchenne muscular dystrophy (DMD) treatment SRP-9001 (delandistrogene moxeparvovec) after already winning US Food and Drug Administration accelerated approvals for three exon-skipping DMD drugs. However, as a one-time gene therapy with a potentially high upfront cost, SRP-9001 may face a different type of scrutiny once it hits the market – though that will likely be several months before its closest competitor.

Given that Sarepta investors have mostly focused this year on whether or not the biotech would try to beat

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Gene Therapies

More from Advanced Therapies